Abstract
There are several therapeutic modalities to treat various types of skin cancer. In general, in the early stages of most common skin cancers, the surgical option by removing the tumor and leaving an adequate oncologic margin is usually the best and most used option; in addition, surgery generally offers the best chance of cure with the advantage of having histopathologic evaluation of the excised margins. In other less frequent malignant neoplastic diseases such as mycosis fungoides and Kaposi’s sarcoma, topical treatment is an option and even a choice option in the early stages of the disease.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Miller SJ, Moresi JM, et al. Actinic keratosis, basal cell carcinoma and squamous cell carcinoma. In: Bolognia JL, editor. Dermatology. 1st ed. Philadelphia: Elsevier Mosby; 2003.
Greenway HT, Maggio KL, et al. Mohs micrographic surgery and cutaneous oncology. In: Robinson JK, editor. Surgery of the skin. Procedural Dermatology. Philadelphia: Elsevier Mosby; 2005.
Ceilley RI, Del Rosso JQ. Topical chemotherapy for the treatment of skin cancer. In: Rigel DS, editor. Cancer of the skin. Madrid: 1st ed. Elsevier; 2004.
Wyatt EL, Sutter SH, Drake LA. Dermatological pharmacology. In: Hardman JG, Limbird LE, editors. Goodman & Gilman’s the pharmaceutical basis of therapeutics. 10th ed. New York: McGraw Hill; 2001.
Amini S, Viera MH, Valins W, Berman B. Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol. 2010;3(6):20–34.
Bargman H, Hochman J. Topical treatment of Bowen’s disease with 5-fluorouracil. J Cutan Med Surg. 2003;7(2):101–5.
Gross K, Kircik L, Kricorian G. 5 % 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33:433–40.
Epstein E. Fluorouracil paste treatment of thin basal cell carcinoma. Arch Dermatol. 1985;121:207–13.
Orenberg EK, Miller BH, Greenway HT, Koperski JA, Lowe N, Rosen T, et al. The effect of intralesional 5-fluorouracil therapeutic implant (MPI 5003) for treatment of basal cell carcinoma. J Am Acad Dermatol. 1992;27:723–8.
Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145:1431–8.
Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis-a systematic review of randomized controlled trials. Int J Dermatol. 2009;48(5):453–63.
Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42(1 Pt 2):25–8.
Epstein E. Treatment of lip keratoses (actinic cheilitis) with topical fluorouracil. Arch Dermatol. 1977;113(7):906–8.
Kossow AS, Cotelingam JD, MacFarland F. Bowenoid papulosis of the penis. J Urol. 1981;125(1):124–6.
Litt JZ. Pocketbook of drug eruptions and interactions. New York: Parthenon Publishing; 2004.
Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5 % cream in the treatment of Bowen’s disease. J Am Acad Dermatol. 2001;44(3):462–70.
Wu JK, Siller G, Whitehead K. Treatment of Bowen’ disease and basal cell carcinoma of the nose with imiquimod 5 % cream. Australas J Dermatol. 2003;44(2):123–5.
Schroeder TL, Sengelmann RD. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5 % cream. J Am Acad Dermatol. 2002;46(4):545–8.
Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5 % cream. J Am Acad Dermatol. 1999;41:1002–7.
Geisse J, Rich P, Pandya A, et al. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: a double blind randomized, vehicle controlled study. J Am Acad Dermatol. 2002;47:390–8.
Berman B, Villa A. Moduladores inmunitarios en el tratamiento del cancer de piel. In: Rigel DS, editor. Cancer de piel. 1st ed. Madrid: Elsevier; 2006.
Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722–33.
Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5 % cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939–47.
Gollnick H, Barona CG, Frank RGJ, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5 % cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol. 2005;15(5):374–81.
Eigentler TK, Kamin A, Weide BM, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5 % cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007;57(4):616–21.
Edwards L, Owens ML, Andres KL, et al. A pilot study evaluating imiquimod 5 % cream versus vehicle in the treatment of actinic keratoses. Poster presented at the 58th annual meeting of the American Academy of Dermatology, San Francisco, 10–15 Mar 2000.
Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5 % topical imiquimod cream: an open-label trial. J Am Acad Dermatol. 2002;47(4):571–7.
Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, open-label study using imiquimod 5 % cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007;157 Suppl 2:41–6.
Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5 % cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51(4):547–55.
Gupta AK, Davey V, McPhail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9(5):209–14.
Smith KJ, Germain M, Yeager J, Skelton H. Topical 5 % imiquimod for the therapy of actinic cheilitis. J Am Acad Dermatol. 2002;47(4):497–501.
Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol. 2000;143(4):843–5.
Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149 Suppl 66:66–70.
Van Meurs T, Van Doorn R, Kirtschig G. Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients. Dermatol Surg. 2010;36(6):853–8.
Demirci H, Shields CL, Bianciotto CG, Shields JA. Topical imiquimod for periocular lentigo maligna. Ophthalmology. 2010;117(12):2424–9.
Narayan R, Nguyen H, Bentow JJ, et al. Immuno modulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol. 2012;132:163–9. doi:10.1038/jid.2011.247.
Sigüenza M, Pizarro A, Mayor M, et al. Tratamiento tópico de las metástasis cutáneas de melanoma con imiquimod. Actas Dermosifiliogr. 2005;96(2):111–5.
Turza K, Dengel LT, Harris RC, et al. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol. 2010;37(1):94–8.
de Quatrebarbes J, Estève E, Bagot M, et al. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol. 2005;141(9):1117–20.
Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther. 2003;16(4):288–98.
Zackheim HS. Topical carmustine (BCNU) for patch/plaque mycosis fungoides. Semin Dermatol. 1994;13(3):202–6.
Zackheim HS, Epstein Jr EH, McNutt NS, et al. Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience. J Am Acad Dermatol. 1983;9(3):363–74.
González-de-Arriba A, Pérez-Gala S, Goiriz-Valdés R, Ríos-Buceta L, García-Díez A. Sarcoma de Kaposi clásico tratado con alitretinoína tópica. Actas Dermosifiliogr. 2007;98(1):50–3.
Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1 % in cutaneous AIDS-related Kaposi’s sarcoma. Am J Clin Dermatol. 2001;2(2):77–87.
Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002;138(3):325–32.
Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801–15.
Nelson C, Rigel D. Long-term follow up of diclofenac sodium 3 % in 2.5 % hyaluronic acid gel for actinic keratosis: One-year evaluation. J Clin Aesthet Dermatol. 2009;2(7):20–5.
Wolf Jr JE, Taylor JR, Tschen E, Kang S. Topical 3.0 % diclofenac in 2.5 % hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709–13.
Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0 % diclofenac sodium topical gel (Solaraze™). J Drugs Dermatol. 2004;3(4):401–7.
Clive S, Leonard RCF. Miltefosine in recurrent cutaneous breast cancer. Lancet. 1997;349:621–2.
Terwogt JMM, Mandjes IAM, Sindermann H, Beijnen JH, BokkelHuinink WW. Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. Br J Cancer. 1999;79(7/8):1158–11613.
Epstein JB, Wong FL, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial. Head Neck. 1994;16:539–44.
Epstein JB, Gorsky M, Wong FL, Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer. 1998;83:629–34.
Watring WG, Roberts JA, Lagasse LD, Berman ML, Ballon SC, Moore JG, et al. Treatment of recurrent Paget’s disease of the vulva with topical bleomycin. Cancer. 1978;41:10–1.
Poignonec S, Lachiver LD, Lamas G, et al. Intralesional bleomycin for acquired inmuno-deficiency syndrome-associated cutaneous Kaposi’s sarcoma. Arch Dermatol. 1995;131:228.
Jorizzo J, Carney P, Ko W. Treatment options in the management of actinic keratosis. Cutis. 2004;74:9–17.
Barrera MV, Herrera E. Tratamiento quimioterápico tópico de la queratosis actínica y el cáncer cutáneo no melanoma: situación actual y perspectivas. Actas Dermosifiliogr. 2007;98(8):556–62.
Graaf YGL, Euvrard S, Bavinck JNB. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg. 2004;30:656–61.
Marshall J. Treatment of solar keratoses with topically applied cytostatic agents. Br J Dermatol. 1968;80:540–2.
Grimaitre M, Etienne A, Fathi M, Piletta PA, Saurat JH. Topical colchicine therapy for actinic keratoses. Dermatology. 2000;200:346–8.
Akar A, BulentTastan H, Erbil H, Arca E, Kurumlu Z, Gur AR. Efficacy and safety assessment of 0.5 % and 1 % colchicine cream in the treatment of actinic keratoses. J Dermatolog Treat. 2001;12:199–203.
Wolf P, Maier H, Müllegger R, Chadwick CA, Hofmann-Wellenhof R, Soyer HP, et al. Topical treatment with liposomes containing T4 endonuclease V protects human skin in vivo from ultraviolet-induced upregulation of interleukin-10 and tumor necrosis factor-α. J Invest Dermatol. 2000;114:149–56.
Zahid S, Brownell I. Repairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapy. J Drugs Dermatol. 2008;7(4):405–8.
Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159(1):205–10.
Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64(8):2833–9.
Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16–22.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Glossary
- Alitretinoin
-
9-cis Retinoic Acid
- Nitrogen Mustard
-
Mechlorethamine hydrochloride
- 5-FU
-
5-Fluorouracil
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
López, M.A. (2014). Topical Treatment. In: Baldi, A., Pasquali, P., Spugnini, E. (eds) Skin Cancer. Current Clinical Pathology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4614-7357-2_20
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7357-2_20
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4614-7356-5
Online ISBN: 978-1-4614-7357-2
eBook Packages: MedicineMedicine (R0)